-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
April 2016
-
Afatinib Outperforms Gefitinib in Advanced Non-Small Cell Lung Cancer
By Erik J. MacLaren, PhD The pan-ErbB inhibitor afatinib (Gilotrif) improves progression-free survival (PFS), time-to-treatment-failure (TTF) rate, and objective response rate (ORR) compared to the first-generation EGFR inhibitor gefitinib (Iressa) as a first-line treatment in patients with EGFR mutation-positive NSCLC, according to results presented at the ESMO Asia 2015 Congress in Singapore.1 Afatinib and gefitinib…
-
Best of the 16th WCLC in Athens, Greece
The International Association for the Study of Lung Cancer (IASLC) and the Oncology Unit of the 3rd Department of Medicine, Medical School of Athens, “Sotiria” Hospital, Greece organized and hosted the Best of the 16th World Conference of Lung Cancer (WCLC) in Athens, Greece, on January 14, 2016. The conference was successful. Almost 400 doctors…
-
FDA Corner – Interview with Gideon Blumenthal, MD
By Erik J. Mac Laren, PhD In 2015, the US Food and Drug Administration (FDA) approved an unprecedented 7 new drugs or new uses for drugs for patients with lung cancer, an increase driven by the proliferation of targeted therapies in the area of thoracic oncology. The advent of precision medicine in oncology has raised…
-
NCI Corner – Interview with Shakun Malik, MD
By Erik J. Mac Laren, PhD In late 2015, the US National Cancer Institute (NCI) Thoracic Malignancy Steering Committee (TMSC) published its strategic priorities for the coming years. These include: (1) innovative clinical trials to facilitate the development of immunotherapies and targeted therapies; (2) rapid testing of new agents to treat small cell lung cancer…
-
Implementation of Lung Cancer CT Screening: A Global Dream or a Real Possibility?
By Professor John K. Field MA, PhD, BDS, FRCPath The advent of lung cancer computed tomography (CT) screening was initiated by the Early Lung Cancer Action Project (ELCAP) group in 19991 with their seminal publication in Lancet. This focused attention on the possibility of introducing CT screening as an early detection strategy, resulting in the…
-
Clinicians and Tobacco—What Can We Really Do?
By Emily Stone, MBBS, MMed, FRACP, and Graham Warren, MD, PhD Tobacco control is set to become one of the most clinically effective and rapidly developing areas in lung cancer medicine. Since the original publication of the US Surgeon General’s Report (SGR) on Smoking and Health in 1964, the 2014 SGR report details the most…
-
Lung Cancer Survivor Wins Trip to US NFL 2016 Pro Bowl
By Nicola M. Parry, DVM Lung cancer survivor Kathy Weber is an ardent ambassador for the International Association for the Study of Lung Cancer (IASLC). “My involvement with the IASLC comes from attending the World Conference on Lung Cancer (WCLC), as well as a survivors’ get-together at their main office,” she explained, emphasizing how impressed…
-
Memoir Resonates with Oncologists and Patients with Lung Cancer
By Lori Alexander, MTPW, ELS, MWC How does a person with stage IV lung cancer live a meaningful life? That’s the question Paul Kalanithi explores in When Breath Becomes Air, the number 1 book on the New York Times Best Sellers list. Kalanithi’s moving and honest reflection of his life as he transforms from physician…
-
Nurses Treating Lung Cancer, IASLC and Beyond
By Beth Eaby-Sandy, MSN, CRNP, OCN As a nurse practitioner in an academic center in the US, I work in a thoracic medical oncology practice; however, in the US, it is uncommon for nurses or other advanced practice providers to specialize in one cancer disease site. According to the NCI website, 85% of oncology patients…
-
Update on Checkpoint Inhibitors in Lung Cancer
By Erik J. MacLaren, PhD The growing number of checkpoint inhibitors currently being developed, without question, has ushered in a new era in clinical oncology, particularly in the treatment of thoracic malignancies.These agents block various components of the immune checkpoint pathway, such as programmed cell death-1 (PD-1) receptor, which is expressed on the surface of…